Nordic Life Science 1
HÅKAN FRÖDERBERG has experience from leading posi
tions in several companies within the life science industry. He started at A+ Science on August 17. He replaces Martin Tiberg who has been interim CEO since April 2, 2020, when Jennifer Heyno left the company. Before joining A+ Science, Fröderberg worked at Celgene as a Business Unit Director and was a member of the Nordic management team. Prior to that, he was the Nordic CEO of Nigaard Pharma/Zambon, where he built the current organization. During his career in the pharmaceutical industry, he has also worked at Vifor Pharma Nordiska, Wyeth, SBL Vaccin and AstraZeneca. “Håkan is an experienced leader with a broad network within the Nordic life science sector and it is inspiring to work together with Håkan and continue to develop A+ Science,” says Mikael Nordenstjerna, Chairman, A+ Science. RAVI RAO has been appointed Head of R&D, as Milan Zdravkovic will pursue other opportunities outside of Sobi. Rao joins from Aeglea Biotherapeutics where he was CMO. His previous experience includes roles at GSK, where he was Vice President, Global Medical Head, Immunology and Specialty Medicine Franchise, as well as Vice President and Medicines Development Leader in Immuno-inflammation R&D. Prior to this he was Group Medical Director, Immunology Clinical Development at Roche Pharmaceuticals. Ravi has experience in early and late stage development, as well as medical affairs in immunology, specialty care and rare diseases. He received his MB BCh from Cambridge University and PhD from Imperial College and is a Member of the Royal College of Physicians, London and an Honorary Member of the Faculty of Pharmaceutical Medicine post-doctoral fellow at Harvard University. ANNI NIEMINEN-VIHERIÄRANTA’S background is in cancer cell biology and metabolic reprogramming. Nieminen-Viheriäranta completed her PhD on cancer and apoptosis in the Faculty of Medicine, University of Helsinki, in 2014. After that, she has worked as an Academy of Finlandfunded Postdoctoral fellow at Nutrient Sensing Lab in Finland and at the CRUK Beatson Institute in Glasgow, in Karen Vousden’s lab. “I have always found metabolism exciting because of its complex regulation, diverse pathways and defects in diseases,” says NieminenViheriäranta. After the first three months at FIMM, she feels excited and positive that the FIMM Metabolomics Unit will already this fall start providing high quality analysis services for fluxomics and metabolic profiling customized for diseases and research questions, she says. BECKI MORISON joined the Global Leadership Team as Executive Vice President, Global Therapeutic & Value Strategy, LEO Pharma, on October 1, 2020. Morison joins LEO Pharma from Eli Lilly, where she was VP, US Immunology. Prior to that, she held several leadership positions In addition to her international experience, Morison has a proven track record in building and growing innovative pharmaceutical franchises in different therapeutic areas, including orphan diseases. “Morison’s broad knowledge in immunology, dermatology and specialty pharma will help us to strategically develop our portfolio and execute global launches, which is essential to reach our ambition of becoming a global leader in medical dermatology,” says Catherine Mazzacco, CEO, LEO Pharma. Becki Morison succeeds Patrice Baudry, who will take over responsibility for establishing LEO Pharma’s rare disease presence. 30 NORDICLIFESCIENCE.ORG